Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome
Authors:
Open Access
- 11 December 2018
- journal article
- research article
- Published by Springer Nature in Blood Cancer Journal
- Vol. 8 (12) , 1-7
Abstract
Overall survival (OS) of multiple myeloma has improved remarkably over time, with the recent Intergroupe Francophone du Myelome (IFM) 2009 randomized trial reporting a 4-year OS rate of approximately 82% in patients receiving modern therapy. However, survival estimates from clinical trials may overestimate outcomes seen in clinical practice even with the adjustment for age and other key characteristics. The purpose of this study was to determine the OS of myeloma patients seen in routine clinical practice who resembled the cohort studied in the IFM 2009 trial. A second goal was to conduct a brief comparative effectiveness analysis of bortezomib, lenalidomide, dexamethasone, and other major induction regimens used during the study period. We studied all patients with myeloma 65 years of age and younger, seen at the Mayo Clinic between January 1, 2010 and August 31, 2015, who had a stem cell harvest performed within 12 months of initial diagnosis. Patients with baseline serum creatinine >2 mg/dL were excluded. Five hundred and eighteen patients were studied. The 4-year OS rate was 82.3%, comparable to results achieved in the contemporaneous IFM randomized trial. The 4-year OS rates for standard and high-risk myeloma were 86.3% and 68.2%, respectively.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA 107476, CA 168762, CA 186781, CA 107476, CA 168762, CA 186781)
This publication has 24 references indexed in Scilit:
- Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myelomaBlood Cancer Journal, 2018
- The multiple myelomas — current concepts in cytogenetic classification and therapyNature Reviews Clinical Oncology, 2018
- Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignanciesBlood Cancer Journal, 2018
- Long-Term Follow-up of Monoclonal Gammopathy of Undetermined SignificanceNew England Journal of Medicine, 2018
- Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survivalBlood Cancer Journal, 2017
- Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myelomaBlood Cancer Journal, 2017
- Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for MyelomaNew England Journal of Medicine, 2017
- Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic markerBlood Cancer Journal, 2017
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupJournal of Clinical Oncology, 2015
- Trisomies in multiple myeloma: impact on survival in patients with high-risk cytogeneticsBlood, 2012